Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc Targeted Oncology Panel at Citi Biopharma Co-Panel Day (Virtual) Transcript

May 18, 2022 / 05:30PM GMT
Release Date Price: $13.64 (-6.77%)
Yigal Dov Nochomovitz;Yujiro S. Hata
Citigroup Inc., Research Division - Director;IDEAYA Biosciences, Inc. - Co-Founder, CEO, President &

Okay. Great. Welcome, everyone, to the Targeted Oncology panel. My name is Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. It's my pleasure to have with me 4 CEOs from important Targeted Oncology companies. From Ideaya, Yujiro Hata, who's the Co-Founder and CEO; from Oric, Jacob Chacko, President and CEO; and from Rain, Avanish Vellanki CEO; and finally, from Syndax, Michael Metzger, also CEO. So gentlemen, welcome all of you. Thank you very much for taking a bit of time out of your super busy schedules to chat.

So I think to start out to level set, if you wouldn't mind just for each of you running through very, very quickly 1, 2 minutes, just a very brief introduction to the company, the key pipeline levers. And then as well, please just mention the catalysts that are coming up for your pipeline in the next 6 to 18 months. That would be great. Maybe if you could just go down the list starting with Yujiro.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot